YL201 + serplulimab

YL201 + serplulimab is an investigational **combination regimen** for cancer treatment, currently being evaluated in phase Ib clinical studies for extensive-stage small cell lung cancer (ES-SCLC). - **YL201** is an antibody-drug conjugate (ADC) targeted against B7-H3. It utilizes a humanized monoclonal antibody conjugated to a proprietary topoisomerase 1 inhibitor (YL0010014) via a protease-cleavable linker, designed to deliver cytotoxic payload directly to tumor cells expressing B7-H3[1][3]. - **Serplulimab** is a fully humanized monoclonal antibody that targets PD-1 (programmed cell death protein 1), functioning as an immune checkpoint inhibitor to restore T-cell-mediated anti-tumor responses[2][6]. This combination aims to leverage YL201's targeted cytotoxicity with serplulimab's immunomodulatory activity against tumor cells. Clinical trials assess safety, tolerability, pharmacokinetics, and efficacy primarily in ES-SCLC[3].